Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Transcode Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +8 vs. Q1 2024
- Shares held
- 262.1K
- −154.9K (−37.1%) vs. Q1 2024
- Total value
- $263.0K
- −$21.1K (−7.4%) vs. Q1 2024
- New holders
- 10
- 1 more added
- Sold out
- 2
- 2 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $208.1K |
| Q1 2026 | 8 | $265.7K |
| Q4 2025 | 6 | $26.4K |
| Q3 2025 | 8 | $155.0K |
| Q2 2025 | 9 | $237.0K |
| Q1 2025 | 19 | $1.06M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 15 | $263.0K |
| Q1 2024 | 7 | $284.1K |
| Q4 2023 | 13 | $105.4K |
| Q3 2023 | 11 | $281.6K |
| Q2 2023 | 5 | $476.6K |
| Q1 2023 | 11 | $88.6K |
| Q4 2022 | 18 | $222.5K |
| Q3 2022 | 13 | $2.27M |
| Q2 2022 | 13 | $2.67M |
| Q1 2022 | 13 | $3.14M |
| Q4 2021 | 16 | $5.98M |
| Q3 2021 | 17 | $7.28M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 74,924 | $75.3K | 0.00% | +74,924 | New |
| Geode Capital Management, LLC | 38,398 | $38.6K | 0.00% | +38,398 | New |
| Citadel Advisors LLC | 25,512 | $25.6K | 0.00% | +25,512 | New |
| Susquehanna International Group, LLP | 24,253 | $24.4K | 0.00% | +24,253 | New |
| Sheets Smith Wealth Management | 20,138 | $20.2K | 0.00% | +20,138 | New |
| Virtu Financial LLC | 18,358 | $18.0K | 0.00% | −36,971−66.8% | Reduced |
| Private Capital Management LLC | 17,518 | $17.6K | 0.00% | +17,518 | New |
| Two Sigma Securities, LLC | 12,854 | $12.9K | 0.00% | −9,121−41.5% | Reduced |
| Captrust Financial Advisors | 11,250 | $11.3K | 0.00% | +11,250 | New |
| Morgan Stanley | 10,000 | $10.1K | 0.00% | +10,000 | New |
| Tower Research Capital LLC (TRC) | 7,873 | $7.91K | 0.00% | +2,946+59.8% | Added |
| Financial Network Wealth Advisors LLC | 1,000 | $1.00K | 0.00% | +1,000 | New |
| Bank of America Corp | 55 | $55 | 0.00% | +55 | New |
| First Personal Financial Services | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 0 | $0 | 0.00% | −334,823−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −5−100.0% | Sold out |